About Takara Bio
Takara Bio is a company based in Frankfurt (Germany) founded in 1925. The company has 1,780 employees as of March 31, 2024. Takara Bio has completed 4 acquisitions, including Clontech, Curio Bioscience and Rubicon Genomics. Takara Bio operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
- Headquarter Frankfurt, Germany
- Employees 1780 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Takara Bio Inc.
-
Annual Revenue
$301.41 M (USD)3.53as on Mar 31, 2025
-
Net Profit
$6.96 M (USD)-29.64as on Mar 31, 2025
-
EBITDA
$45.1 M (USD)-15.95as on Mar 31, 2025
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
1780
as on Mar 31, 2024
-
Investments & Acquisitions
Clontech
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Takara Bio
Takara Bio is a publicly listed company on the TSE with ticker symbol 4974 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Takara Bio
Unlock access to complete
Funding Insights of Takara Bio
Detailed funding history for Takara Bio
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Takara Bio
Takara Bio has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Clontech, Curio Bioscience and Rubicon Genomics.
Investment portfolio details for Takara Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Spatial omics solutions are provided for discovery research.
|
Locked | Locked | 2021 | Locked | |
|
Genomic tools are provided for resequencing, genotyping, and expression analysis.
|
Locked | Locked | 2002 | Locked | |
|
Reagents and kits for pre-analytical amplification technologies are supplied.
|
Locked | Locked | 2000 | Locked |
Complete acquisition details for Takara Bio
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Takara Bio
Detailed financials for Takara Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Takara Bio Comparisons
Peer comparison for Takara Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Takara Bio
Takara Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
Detailed competitors of Takara Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Takara Bio
Complete news archive for Takara Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Takara Bio
Takara Bio was founded in 1925.
Takara Bio is headquartered in Frankfurt, Germany. It is registered at Frankfurt, Hesse, Germany.
As of Mar 31, 2024, the latest employee count at Takara Bio is 1,780.
Annual revenue of Takara Bio is $301.41M as on Mar 31, 2025.
Takara Bio was founded in 1925 and is headquartered in Frankfurt, Germany. Gene-based therapies are developed by the company, including HF10, an oncolytic herpes simplex virus strain for antitumor activity, MAGE-A4 antigen-specific TCR gene therapy targeting esophageal cancer with retroviral vectors, and MazF-modified T-cells for HIV RNA cleavage. Contract services are also provided to the industrial and agricultural sectors in the biotechnology field.
Takara Bio's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Yes, Takara Bio is publicly traded on TSE under the ticker symbol 4974.
Takara Bio has made 4 acquisitions, including Clontech, Curio Bioscience, and Rubicon Genomics.
The ticker symbol of Takara Bio is 4974 on TSE.